Related Experiment Video
Updated: Jan 19, 2026

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
Published on: August 26, 2013
A Bone Morphogenetic Protein (BMP)-derived Peptide Based on the Type I Receptor-binding Site Modifies Cell-type
Zhen Tong1, Jingxu Guo1, Robert C Glen2,3
1The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0QQ, United Kingdom.
Researchers designed a novel peptide mimetic (P3) from bone morphogenetic protein 9 (BMP9). This P3 peptide selectively enhances BMP9 signaling in certain cells and modulates BMP signaling in a cell-specific manner, offering potential for BMP-based therapies.
Area of Science:
- Biochemistry and Molecular Biology
- Cell Signaling and Receptor Interactions
- Drug Discovery and Development
Background:
- Bone morphogenetic proteins (BMPs) are crucial signaling molecules with therapeutic potential, but designing specific mimetics is challenging.
- Understanding BMP receptor interactions is key to developing targeted BMP-based therapies.
- The transforming growth factor β (TGFβ) superfamily includes BMPs, known for diverse biological functions.
Purpose of the Study:
- To design and characterize a peptide mimetic of BMP9 with specific receptor binding and signaling modulation capabilities.
- To investigate the cell-type-specific effects of the BMP9 peptide mimetic on BMP signaling pathways.
- To explore the translational potential of BMP mimetics in therapeutic applications.
Main Methods:
- Design of a BMP9 peptide mimetic (P3) based on the type I receptor binding site.
- Assessment of binding affinities to activin receptor like kinase (ALK) receptors (ALK1, ALK2, ALK3).
- Evaluation of P3's effect on BMP9- and BMP4-induced Smad1/5 phosphorylation and gene expression in various cell types (hPAECs, dermal microvascular endothelial cells, C2C12 myoblasts).
Main Results:
- The BMP9 peptide mimetic P3 exhibited millimolar binding affinities for ALK1, ALK2, and ALK3.
- P3 selectively enhanced BMP9-induced signaling in human pulmonary artery endothelial cells (hPAECs) via ALK1, dependent on alpha helix propensity.
- P3 modulated BMP signaling differently across cell types, inhibiting BMP4-induced signaling in dermal microvascular endothelial cells and showing no effect on BMP9-induced osteogenic signaling in C2C12 cells.
Conclusions:
- A BMP9-derived peptide mimetic (P3) was successfully designed, demonstrating selective enhancement of BMP9/ALK1 signaling in hPAECs.
- The peptide P3 exhibits cell-type-specific modulation of BMP9 and BMP4 signaling pathways.
- These findings highlight the potential of rationally designed peptide mimetics for targeted BMP-based therapeutic strategies.
Related Concept Videos
10:23Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
11:20Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
10:13Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Types of Hormones
Types of Receptors: Cell Surface Receptors
14:28Peptide-based Identification of Functional Motifs and their Binding Partners

